Chronic nicotine attenuates behavioral and synaptic plasticity impairments in a Streptozotocin model of Alzheimer’s disease

Brain glucose metabolism is altered in sporadic Alzheimer’s disease (sAD), whose pathologies are reproduced in rodents by intracerebroventricular (icv) infusion of streptozotocin (STZ) in subdiabetogenic doses. The icv- STZ model also culminates in central cholinergic dysfunctions, which in turn are...

Full description

Access type:openAccess
Publication Date:2017
Main Author: Esteves, I. M.
Other Authors: Lopes-Aguiar, C., Ruggiero, R. N., Broggini, A. C. S., Bueno-Junior, L. S., Kandratavicius, L., Monteiro, M. R., Romcy-Pereira, R. N., Leite, J. P.
Document type: Article
Language:eng
Portuguese subjects:
Online Access:https://repositorio.ufrn.br/jspui/handle/123456789/23358
Portuguese abstract:Brain glucose metabolism is altered in sporadic Alzheimer’s disease (sAD), whose pathologies are reproduced in rodents by intracerebroventricular (icv) infusion of streptozotocin (STZ) in subdiabetogenic doses. The icv- STZ model also culminates in central cholinergic dysfunctions, which in turn are known to underlie both the sAD cognitive decline, and synaptic plasticity impairments. Considering the cognitive-enhancing potential of chronic nicotine (Nic), we investigated whether it attenuates icv- STZ-induced impairments in recognition memory and synaptic plasticity in a cognition-relevant substrate: the hippocampal CA1-medial prefrontal cortex (mPFC) pathway. Rats treated with icv-STZ were submitted to a chronic Nic regime, and were evaluated for recognition memory. We then examined long-term potentiation (LTP), paired-pulse facilitation (PPF) under urethane anesthesia, and brains were also evaluated for hippocampus-mPFC cell density. We found that Nic treatment prevents icv-STZ-induced disruptions in recognition memory and LTP. STZ did not precipitate neuronal death, while Nic alone was associated with higher neuronal density in CA1 when compared to vehicle-injected animals. Through combining behavioral, neurophysiological, and neuropathological observations into the Nic-STZ interplay, our study reinforces that cholinergic treatments are of clinical importance against earlystage Alzheimer’s disease and mild cognitive impairments